Valuation: Replimune Group, Inc.

Market Cap 923M 807M 744M 687M 1.3B 87.99B 1.33B 8.89B 3.49B 43.35B 3.46B 3.39B 149B P/E 2027 *
-5.18x
P/E 2028 * -8.83x
Enterprise Value 906M 792M 731M 675M 1.28B 86.37B 1.3B 8.73B 3.43B 42.55B 3.4B 3.33B 146B EV / Sales 2027 *
27x
EV / Sales 2028 * 13.2x
Free-Float
97.44%
Yield 2027 *
-
Yield 2028 * -
1 day-1.08%
1 week-5.09%
Current month-0.72%
1 month+23.76%
3 months+130.88%
6 months+35.60%
Current year+13.07%
1 week 10.46
Extreme 10.46
11.85
1 month 8.62
Extreme 8.625
12.5
Current year 1.5
Extreme 1.5
12.5
1 year 1.5
Extreme 1.5
13.24
3 years 1.5
Extreme 1.5
22.21
5 years 1.5
Extreme 1.5
36.97
10 years 1.5
Extreme 1.5
54.85
Manager TitleAgeSince
Chief Executive Officer 55 2024-03-31
Director of Finance/CFO 46 2023-09-18
Chief Tech/Sci/R&D Officer 60 2022-11-30
Director TitleAgeSince
Chairman 54 2024-03-31
Director/Board Member 66 2017-06-30
Chairman 65 2020-03-31
Date Insider Type Main position Quantity % Market Cap.
05-31Sell

Chief Commercial Officer

-12,000 0.0154%
05-17Sell

Controller/Auditor

-7,894 0.0101%
05-17Sell

Chief Technology Officer

-14,023 0.0180%
Change 5-day change 1-year change 3-year change Capi.($)
-1.08%-5.09%+0.18%-45.59% 923M
-0.36%+0.79%+3.61%+10.13% 50.73B
-2.22%-1.25%+391.53%+593.69% 39.73B
-0.54%+0.39%+27.67%-5.10% 34.69B
-1.36%+0.35%+19.34%+55.53% 33.21B
+1.21%-4.58%+3.00%+31.73% 26.76B
-1.81%-1.48% - - 16.8B
+0.51%-3.47%+66.38%+122.57% 15.37B
+0.35%+0.73%+15.03%+16.81% 13.78B
-0.62%-3.09%+11.43%-31.02% 12.85B
Average -0.59%-1.26%+59.80%+83.19% 24.48B
Weighted average by Cap. -0.67%-0.25%+82.42%+124.07%

Financials

2027 *2028 *
Net sales 33.54M 29.34M 27.06M 24.99M 47.43M 3.2B 48.22M 323M 127M 1.58B 126M 123M 5.42B 69.91M 61.15M 56.41M 52.1M 98.85M 6.67B 101M 674M 265M 3.28B 263M 257M 11.29B
Net income -205M -180M -166M -153M -290M -19.58B -295M -1.98B -777M -9.65B -771M -754M -33.17B -148M -129M -119M -110M -209M -14.12B -213M -1.43B -560M -6.95B -556M -544M -23.91B
Net Debt -17M -14.87M -13.72M -12.67M -24.04M -1.62B -24.44M -164M -64.36M -799M -63.83M -62.44M -2.75B -
Logo Replimune Group, Inc.
Replimune Group, Inc. is a clinical-stage biotechnology company engaged in the development of novel oncolytic immunotherapies. Its proprietary RPx platform is based on a potent HSV-1 backbone intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The RPx platform is designed to have a unique dual local and systemic activity consisting of direct selective virus-mediated killing of the tumor resulting in the release of tumor-derived antigens and altering of the tumor microenvironment to ignite a systemic response. Its lead product candidate, RP1, is a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF. Its lead indication for its lead product candidate, RP1, is the potential treatment of advanced melanoma. Its pipeline product candidates include RP2 and RP3. It has designed its RP2 product candidate to express an anti-CTLA-4 antibody-like protein intended to block the inhibition of the immune response.
Employees
465
Date Price Change Volume
26-07-10 US$10.99 -1.08% 2,304,568
26-07-09 US$11.11 -0.09% 2,744,923
26-07-08 US$11.12 -3.39% 3,269,454
26-07-07 US$11.51 +0.35% 2,097,143
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
8
Last Close Price
10.99USD
Average target price
10.67USD
Spread / Average Target
-2.94%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. REPL Stock